Cargando…
Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy
BACKGROUND: Solid tumor hypoxic conditions prevent the generation of reactive oxygen species (ROS) and the formation of DNA double-strand breaks (DSBs) induced by ionizing radiation, which ultimately contributes to radiotherapy (RT) resistance. Recently, there have been significant technical advance...
Autores principales: | Wang, Haijun, Jia, Dianlong, Yuan, Dandan, Yin, Xiaolei, Yuan, Fengjiao, Wang, Feifei, Shi, Wenna, Li, Hui, Zhu, Li-Min, Fan, Qing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120847/ https://www.ncbi.nlm.nih.gov/pubmed/33985511 http://dx.doi.org/10.1186/s12951-021-00885-6 |
Ejemplares similares
-
Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer
por: Hu, Xianwen, et al.
Publicado: (2022) -
Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis
por: Liu, Yongsheng, et al.
Publicado: (2022) -
Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution
por: Ding, Haozhong, et al.
Publicado: (2021) -
Cellular Effects of HER3-Specific Affibody Molecules
por: Göstring, Lovisa, et al.
Publicado: (2012) -
DNA–affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy
por: Zhang, Chao, et al.
Publicado: (2019)